Lv6
2050 积分 2023-11-28 加入
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
14天前
已完结
Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats
26天前
已关闭
Radiotherapy toxicities: mechanisms, management, and future directions
27天前
已完结
89Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma
1个月前
已完结
Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
2个月前
已完结
[177Lu]Lu-DOTA-TATE tumour and organ time-activity curves: prediction from a single-time-point [68Ga]Ga-DOTA-TATE PET/CT measurement
2个月前
已关闭
A pilot study on the biodistribution pattern of 68Ga-DOTA-TATE in normal organs of adults
2个月前
已完结
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
2个月前
已完结
Pre-Clinical Assessment of 177Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease
2个月前
已完结
A phase I study of 99mTc-hR3 (DiaCIM®), a humanized immunoconjugate directed towards the epidermal growth factor receptor
2个月前
已完结
皖公网安备34019202002308
